Home / Healthcare/ New GScan screening increases success of pregnancy

New GScan screening increases success of pregnancy


Comments / {{hitsCtrl.values.hits}} Views / Monday, 11 February 2019 00:00

Facebook

 

  • GScan pioneers Sri Lanka’s first Non Invasive Pre-natal Testing and Pre-implantation Genetic Screening

 

Credence Genomics Ltd., Sri Lanka’s pioneer in clinical genomics and only Next Generation Sequencing facility has launched GScan range of diagnostics for infertility related issues. Non Invasive GScan (Non Invasive Pre-natal Testing) and IVF GScan (Pre implantation genetic screening) is now available in all leading hospital and leading fertility centres island-wide. The cutting edge screening technology assists in aneuploidy testing and IVF testing increasing success of pregnancy.  

Dr. Padmapani Padeniya
 
Prof. Tiran Dias

Infertility and high-risk pregnancies are a growing medical problem globally usually due to multiple reasons including smoking, late marriages, menstrual irregularities and chronic illnesses to name a few. The GScan diagnostics range will play an assistive role in screening for aneuploidies in foetuses before even being implanted.

The GScan suite of products screen a patient and assist a clinician during various stages of pregnancy. Starting from the inception of IVF the highest success of pregnancy can be achieved when screening with IVF GScan to ensure the optimal time of implantation. Following conception Non-Invasive GScan is a near 100% accurate screening test that assists the clinician along with other routine tests to evaluate the state of the foetus. 

Trusted and used by Sri Lankan clinicians island wide the GScan range of products have replaced risky procedures, like amniocentesis, and still giving the patients and clinicians the answer they need while increasing the success of IVF treatment by double. All tests are conducted at Credence state-of-the-art facility in Kohuwala, Sri Lanka. Led by a team of leading scientists and clinicians Credence continues to offer locally accurate, rapid and cost-effective screening tests. Validated locally and internationally the range caters to both local and international healthcare hospitals and fertility centres. 

Professor Tiran Dias a leading consultant in Obstetrics and Gynaecology and Professor in Foetal Medicine said, “GScan represents the future of genomic inclusive screening in the areas of pregnancy and IVF. Credence continues to establish its dominance by serving the region through its innovations bringing world class screening at cost effective prices.”

Credence Genomics also provides genetic counselling to patients to help them understand and adapt to the medical, psychological and familial implications of genetic contributions to the disease. Accompanying the GScan range of products, Credence has a series of products under its GSeek category which allow for screening for a couple who plan to have a child and the genomics health of the child can be checked with GSeek Newborn screening. 

Dr. Padmapani Padeniya, Geneticist and a Genetic Counsellor and also a Senior Lecturer of Ragama Medical Faculty said, “IVF GScan is the new frontier of testing aneuploidy in IVF technology. In fact this test provides the selective screening of embryos before being implanted hence the success rate can be enhanced. Further it will directly reduce the incidence of birth defects in Sri Lanka”. Non-invasive GScan enables the mother to screen the foetus non-invasively at an early as 10 weeks of gestation for commonly available aneuploidies like Down syndrome. 

Credence Chairman/CEO Dr. Vaz Gnanam said, “As we continue to pioneer and develop the latest accurate, tests for the region our commitment to providing the best in health care is represented in our infertility range of GScan products. As a company we believe that this product range will add value to IVF and the general practice of obstetrics and gynaecology.”

 


Share This Article

Facebook Twitter


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS